Search - tctmd.com

Displaying 241 - 260 of 464

Sort: Relevancy | Date

News Conference News ESC 2019

Long-term Secondary Prevention Post-CABG Important Yet Lacking: SWEDEHEART

Yael L. Maxwell

September 04, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

News Daily News

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Michael O'Riordan

August 22, 2019

News Daily News

Acupuncture for Angina? Chinese Study Backs Targeted Approach

Caitlin E. Cox

July 31, 2019

News Daily News

Intensive Lipid-Lowering Slashes CVD in Elderly ACS Patients

Michael O'Riordan

July 19, 2019

News Conference News SCCT 2019

Doubling Down on SCOT-HEART: Mechanisms, Applicability, and Future Directions

Yael L. Maxwell

July 18, 2019

News Daily News

Age Without Atherosclerosis: Tests May Help Elderly Skip Statins

Yael L. Maxwell

July 04, 2019

News Conference News EAS 2019

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Michael O'Riordan

June 07, 2019

News Conference News EAS 2019

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

Michael O'Riordan

June 05, 2019

News Conference News EAS 2019

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

Michael O'Riordan

June 04, 2019

News Conference News SCAI 2019

LDL Apheresis Potentially a ‘Head Start’ to Conventional Lipid-Lowering Methods Post-PCI in ACS: PREMIER

Yael L. Maxwell

June 03, 2019

News Conference News EAS 2019

FH Patients Derive Biggest Absolute Benefit From Statin Therapy: 4S Analysis

Michael O'Riordan

June 03, 2019

News Conference News EAS 2019

Bempedoic Acid/Ezetimibe Combo Lowers LDL Cholesterol in High-Risk Patients

Michael O'Riordan

May 30, 2019

News Conference News EAS 2019

CHD Mortality Significantly Elevated in Patients With Severe FH

Michael O'Riordan

May 29, 2019

News Daily News

Higher Risk of Intracranial Hemorrhage With Aspirin in Primary Prevention

Michael O'Riordan

May 20, 2019

News Daily News

Familial Hypercholesterolemia Seen in 10% of Young MI Patients

Michael O'Riordan

May 15, 2019

News Daily News

Residual Inflammatory Risk and PCI: Worthy Biomarker or Merely Something Else to Measure?

Yael L. Maxwell

May 15, 2019

News Daily News

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Michael O'Riordan

April 29, 2019

News Daily News

EXCEL Insights: CABG Outcomes for Left Main CAD Have Improved Substantially

Michael O'Riordan

April 22, 2019

News Daily News

Visit-to-Visit BP Variability Linked to Coronary Plaque Progression, Adverse Outcomes

Todd Neale

April 11, 2019

Advertisement

Long-term Secondary Prevention Post-CABG Important Yet Lacking: SWEDEHEART

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Acupuncture for Angina? Chinese Study Backs Targeted Approach

Intensive Lipid-Lowering Slashes CVD in Elderly ACS Patients

Doubling Down on SCOT-HEART: Mechanisms, Applicability, and Future Directions

Age Without Atherosclerosis: Tests May Help Elderly Skip Statins

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

LDL Apheresis Potentially a ‘Head Start’ to Conventional Lipid-Lowering Methods Post-PCI in ACS: PREMIER

FH Patients Derive Biggest Absolute Benefit From Statin Therapy: 4S Analysis

Bempedoic Acid/Ezetimibe Combo Lowers LDL Cholesterol in High-Risk Patients

CHD Mortality Significantly Elevated in Patients With Severe FH

Higher Risk of Intracranial Hemorrhage With Aspirin in Primary Prevention

Familial Hypercholesterolemia Seen in 10% of Young MI Patients

Residual Inflammatory Risk and PCI: Worthy Biomarker or Merely Something Else to Measure?

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

EXCEL Insights: CABG Outcomes for Left Main CAD Have Improved Substantially

Visit-to-Visit BP Variability Linked to Coronary Plaque Progression, Adverse Outcomes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content